

Key Investor Information

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

RIZE MEDICAL CANNABIS AND LIFE SCIENCES UCITS ETF: USD Accumulating ETF

Rize UCITS ICAV (the "ICAV")

ISIN: IE00BJXRZ273

The Fund is a sub-fund of Rize UCITS ICAV (the "ICAV").

Managed by Davy Global Fund Management Limited (the "Manager") of the Davy group of companies

Objectives and Investment Policy

FUND. The Rize Medical Cannabis and Life Sciences UCITS ETF (the "**Fund**") is a passively managed exchange traded fund ("ETF") that aims to replicate the performance of the Foxberry Medical Cannabis & Life Sciences USD Net Total Return Index (the "**Index**").

INDEX. The Index is comprised of global publicly-traded companies that are listed on eligible stock exchanges and involved in the medical cannabis and cannabis-related life sciences sectors with a focus on companies in the biotech / pharma and hemp and cannabidiol (CBD) sectors. Companies classified as "Big Pharma" are equally weighted within a fixed group weight of 10% and the remaining companies are weighted according to their relative liquidity (a measure of how actively a company's shares are traded on a daily basis), with no company allowed to have a weight of less than 0.05% or greater than 15%.


TRACKING METHOD. The Fund will primarily invest in the companies contained in the Index in similar proportions to their weightings in the Index. The Fund may also invest in (1) other biotech, medical, pharmaceutical and agri-tech companies and companies providing

ancillary products and services to them that have similar risk and performance characteristics to the companies contained in the Index and (2) financial derivative instruments ("FDIs") which are investments the prices of which are based on the companies contained in the Index and/or the companies described at (1) above.

DIVIDEND POLICY. This Share Class does not intend to pay dividends. Any income which may result from the Fund's investments will be re-invested into the Fund.

DEALING. Shares in this Share Class (the "Shares") are denominated in USD and can be bought and sold on stock exchanges by ordinary investors using an intermediary (e.g. a stockbroker). In normal circumstances, only Authorised Participants may buy and sell Shares directly with the ICAV. Authorised Participants may redeem their Shares on demand in accordance with the "Dealing Timetable" published on <http://www.rizeetf.com>

Risk and Reward Profile



- Historical data may not be a reliable indication for the future.
- The risk category shown is not guaranteed and may shift over time.
- The lowest category does not mean 'risk free'.

The Fund is rated 7 due to the nature of its investments and its risks. The rating is calculated based on historical data and may not be a reliable indication of the Fund's future risk profile. The risk category may shift over time. The lowest category on the above scale does not mean "risk free".

The Fund is vulnerable to cyclical declines in the cannabis sector.

Any change to existing applicable laws or regulations that currently enable companies to engage in cannabis-related business activities ("CRB Activities") would reduce the value of affected companies and the Fund.

Also, some companies may breach such applicable laws or regulations which may (1) cause them to be de-listed from stock exchanges and/or reduce their market value (and therefore reduce the Fund's value or its ability to realise its investments) and/or (2) mean that capital gains or income derived from such companies cause the Fund and/or the Fund's investors to be in breach of anti-money laundering laws or other laws applicable to them respectively ("Applicable Laws").

The Fund may have exposure to the recreational consumer market for cannabis even though it does not intend to. This might mean that the capital gains or income derived from companies with this exposure cause the Fund and/or the Fund's investors to be in breach of Applicable Laws.

A change in any legal requirements relating to funds with cannabis exposure might require the Manager to stop marketing the Fund in certain countries, de-list the Fund's Shares from certain stock exchanges; and/or close the Fund.

The Fund invests in pharmaceutical companies which may never generate revenue due to clinical trial failures and/or a lack of required approvals for new drugs. Such factors could severely reduce the values of affected companies and the Fund. The Fund also invests in small publicly traded companies which may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies.

The Fund invests in global equity securities. As such there is a risk of loss arising from exchange rate fluctuations or exchange control regulations.

Other: (1) Third party service providers (such as the ICAV's depositary) may go bankrupt and fail to pay money due to the Fund or return property belonging to the Fund. (2) If the Index provider stops calculating the Index or if the Fund's license to replicate the Index is terminated, the Fund may have to be closed. (3) It may not always be possible to buy and sell the Fund's Shares on a stock exchange or at prices closely reflecting the Net Asset Value. (4) There is no capital guarantee or protection on the value of the Fund and investors can lose all the capital invested in the Fund. (5) Please refer to the "Risk Factors" section of the ICAV's Prospectus and the Fund Supplement.

Charges

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

| One-off charges taken before or after you invest | |
|---|-----------|
| Entry charge | No charge |
| Exit charge | No charge |
| Charges taken from the Fund over a year | |
| Ongoing charges | 0.65% |
| Charges taken from the Fund under certain specific conditions | |
| Performance fee | No charge |


*Authorised Participants dealing directly with the ICAV will pay dealing-related transaction costs

Investors who buy and sell Shares on stock exchanges are not charged entry or exit charges by the ICAV but may be charged dealing costs and fees by their stockbroker. Please consult your stockbroker and/or investment adviser for details of such fees.

The ongoing charges figure is based on expenses for the financial year ending July 2021. The ongoing charges figure excludes portfolio transaction costs (except for transaction costs paid to the Depositary, which are included).

For more information about charges, please see the "Fees, Costs and Expenses" and "Subscriptions and Redemptions" sections of the ICAV's Prospectus and the "Fees and Expenses" and "Dealing in Shares of the Fund" sections of the Fund Supplement which are available at: <http://www.rizeetf.com>

Past Performance



- The Fund has been in existence since January 2020. This Share Class has been in existence since January 2020.
- Past performance is not an indication of future performance.
- Past performance is calculated in USD.
- The performance figures include all ongoing charges and exclude any entry charges or exit charges.

Practical Information

- Fund Depositary: Northern Trust Fiduciary Services (Ireland) Limited.
- The ICAV is resident in Ireland for taxation purposes. This may have an impact on your personal tax position. Please consult your investment or tax adviser for advice on your own tax liabilities.
- The Manager may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the ICAV's Prospectus.
- Switching of shares between this Share Class and other share classes of the Fund and/or other sub-funds of the ICAV is not permitted.
- The Fund is one of a number of sub-funds of the ICAV. The assets and liabilities of each sub-fund are segregated from each other by Irish law. Although the rights of investors and creditors are normally limited to the assets of each sub-fund, the ICAV is a single legal entity that may operate in jurisdictions which may not recognise such segregation.
- Further information about the Fund and the Share Class can be obtained from the ICAV's Prospectus and Fund Supplement and the annual and interim financial statements (that are prepared for the ICAV as a whole), which are available in English and certain other languages, in addition to the latest available Net Asset Value for the Share Class and details of the Fund's portfolio, at: <http://www.rizeetf.com>
- Details of the Manager's up-to-date policy in respect of remuneration, including a description of how remuneration and benefits are calculated and the identities of the persons responsible for awarding same can be accessed from the following website: <https://www.davygfm.com/binaries/content/assets/davygfm/legal/dgfm-remuneration-policy.pdf>
- An indicative intra-day net asset value ("iNAV") for the Share Class will be available at: <http://www.rizeetf.com>